ARDS (Acute Respiratory Distress Syndrome)
Critical Alerts
- ARDS mortality remains 30-40% even with optimal management
- Lung protective ventilation is the cornerstone of treatment
- Low tidal volume (6 mL/kg IBW) reduces mortality - this is non-negotiable
- Prone positioning for 16+ hours improves survival in moderate-severe ARDS
- Identify and treat the underlying cause - ARDS is a syndrome, not a diagnosis
Key Diagnostics
- Berlin Criteria for diagnosis
- P/F ratio (PaO2/FiO2) on PEEP ≥5 cmH2O
- Chest X-ray or CT (bilateral opacities)
- Echocardiogram (exclude cardiogenic edema)
- Labs to identify underlying cause
Emergency Treatments
- Intubation and mechanical ventilation with lung protective settings
- Tidal volume 6 mL/kg ideal body weight (calculate IBW!)
- Plateau pressure ≤30 cmH2O
- PEEP titration (use PEEP/FiO2 table or driving pressure)
- Prone positioning for P/F <150 (16+ hours/day)
- Conservative fluid strategy after initial resuscitation
Acute Respiratory Distress Syndrome (ARDS) is a form of acute, diffuse, inflammatory lung injury leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. It is characterized by acute onset of hypoxemia and bilateral pulmonary infiltrates not fully explained by cardiac failure.
Berlin Definition (2012)
| Criterion | Definition |
|---|---|
| Timing | Within 1 week of known clinical insult or new/worsening respiratory symptoms |
| Imaging | Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules |
| Origin of edema | Respiratory failure not fully explained by cardiac failure or fluid overload (need objective assessment if no risk factor) |
| Oxygenation | P/F ratio with PEEP ≥5 cmH2O |
Severity Classification
| Severity | P/F Ratio | Mortality |
|---|---|---|
| Mild | 201-300 | 27% |
| Moderate | 101-200 | 32% |
| Severe | ≤100 | 45% |
Epidemiology
- Incidence: 10-80 per 100,000 person-years
- ICU frequency: 10-15% of ICU admissions; 23% of mechanically ventilated patients
- Mortality: 30-40% overall; higher in severe ARDS
- Long-term: Survivors often have persistent functional limitations
Phases of ARDS
Exudative Phase (Days 1-7)
- Diffuse alveolar damage
- Hyaline membrane formation
- Epithelial and endothelial injury
- Protein-rich edema fills alveoli
- Inflammatory cell infiltration
- Surfactant dysfunction
Proliferative Phase (Days 7-21)
- Type II pneumocyte proliferation
- Fibroblast proliferation
- Early fibrosis
- Some resolution begins
Fibrotic Phase (>3 weeks)
- Extensive fibrosis (in some patients)
- Permanent lung architecture changes
- May not occur if early recovery
Lung Mechanics in ARDS
Baby Lung Concept
- Not all lung is damaged equally
- Aerated lung volume is reduced ("baby lung")
- Standard tidal volumes overdistend remaining functional lung
- Regional heterogeneity leads to injury from mechanical ventilation
Mechanisms of Ventilator-Induced Lung Injury (VILI)
| Type | Mechanism |
|---|---|
| Volutrauma | Overdistension from high tidal volumes |
| Barotrauma | High airway pressures |
| Atelectrauma | Repeated opening/closing of collapsed alveoli |
| Biotrauma | Inflammatory mediator release from mechanical stress |
Underlying Causes
Pulmonary (Direct)
| Cause | Frequency |
|---|---|
| Pneumonia | Most common |
| Aspiration | Common |
| Pulmonary contusion | Trauma |
| Inhalation injury | Burns, chemicals |
| Near-drowning | Aspiration |
Extrapulmonary (Indirect)
| Cause | Frequency |
|---|---|
| Sepsis | Most common overall |
| Pancreatitis | Common |
| Massive transfusion | TRALI |
| Trauma/burns | Systemic inflammation |
| Drug overdose | Various mechanisms |
Symptoms and Signs
Symptoms
Physical Examination
| Finding | Significance |
|---|---|
| Tachypnea | Often severe (RR 30-50) |
| Tachycardia | Response to hypoxemia |
| Hypoxemia | Despite supplemental oxygen |
| Accessory muscle use | Increased work of breathing |
| Cyanosis | Severe hypoxemia |
| Crackles | Bilateral, diffuse |
| Decreased breath sounds | Consolidation |
Imaging Findings
Chest X-ray
CT Chest
| Finding | Description |
|---|---|
| Ground-glass opacities | Alveolar filling |
| Consolidation | Complete alveolar filling |
| Dependent consolidation | Gravitational distribution |
| Anterior "baby lung" | Preserved aerated lung |
| Air bronchograms | Within consolidated lung |
Laboratory Findings
Critical Findings
| Red Flag | Concern | Action |
|---|---|---|
| P/F ratio <100 despite high FiO2 | Severe ARDS | Prone positioning, consider ECMO referral |
| Refractory hypoxemia | Failing conventional therapy | ECMO evaluation |
| Plateau pressure >0 cmH2O | Lung overdistension | Reduce Vt, accept permissive hypercapnia |
| pH <7.15 with hypercapnia | Severe respiratory acidosis | May need to increase Vt slightly |
| Hemodynamic instability | ARDS + shock | Careful fluid management, pressors |
| New pneumothorax | Barotrauma | Chest tube, reduce PEEP/Vt |
Poor Prognostic Indicators
- Age >65 years
- Pre-existing organ dysfunction
- Higher APACHE II/III scores
- Failure to improve P/F ratio by day 7
- Underlying cause (sepsis > trauma)
- Immunocompromised status
Conditions Mimicking ARDS
| Condition | Key Features |
|---|---|
| Cardiogenic pulmonary edema | Elevated BNP, responds to diuretics, echo findings |
| Bilateral pneumonia | May meet ARDS criteria - treat underlying cause |
| Pulmonary hemorrhage | Diffuse alveolar hemorrhage, hemoptysis, dropping Hb |
| Acute eosinophilic pneumonia | Eosinophilia on BAL, responds to steroids |
| Cryptogenic organizing pneumonia | Subacute onset, responds to steroids |
| Pulmonary embolism | May have bilateral infiltrates; CT-PA shows PE |
| Lymphangitic carcinomatosis | Cancer history, more gradual onset |
Distinguishing ARDS from Cardiogenic Pulmonary Edema
| Feature | ARDS | Cardiogenic Edema |
|---|---|---|
| BNP | Normal or mildly elevated | Markedly elevated (>00) |
| Echocardiogram | Normal LV function | Reduced EF, elevated filling pressures |
| Response to diuretics | Minimal | Significant improvement |
| Protein in edema fluid | High (exudate) | Low (transudate) |
| PCWP (if measured) | ≤18 mmHg | >8 mmHg |
Establishing Diagnosis
Step 1: Clinical Assessment
- Identify acute respiratory symptoms (<1 week)
- Known or suspected trigger (infection, aspiration, etc.)
- Progressive hypoxemia despite oxygen
Step 2: Oxygenation Assessment
Calculate P/F Ratio:
P/F = PaO2 (from ABG) ÷ FiO2 (as decimal)
Example: PaO2 60 mmHg on FiO2 0.60 → P/F = 100
Must be on PEEP ≥5 cmH2O for Berlin criteria
Step 3: Imaging
- Chest X-ray showing bilateral opacities
- Not fully explained by effusion, atelectasis, nodules
Step 4: Exclude Cardiogenic Cause
- Echocardiogram to assess LV function
- BNP/NT-proBNP
- Clinical context (no history of heart failure, volume overload)
Identify Underlying Cause
| Workup | Purpose |
|---|---|
| Blood cultures | Sepsis |
| Procalcitonin | Bacterial infection |
| Respiratory viral panel | Viral pneumonia |
| Urine Legionella/Pneumococcal | Atypical pneumonia |
| BAL if indicated | Identify pathogen, hemorrhage, eosinophils |
| Lipase | Pancreatitis |
| Drug/toxicology screen | Drug-induced ARDS |
Lung Protective Ventilation (ESSENTIAL)
ARDSNet Protocol
| Parameter | Target |
|---|---|
| Tidal Volume | 6 mL/kg ideal body weight (IBW) |
| Plateau Pressure | ≤30 cmH2O |
| PEEP | Titrate per PEEP/FiO2 table |
| RR | 14-35 to maintain pH goal |
| FiO2 | Lowest to achieve SpO2 88-95% |
| pH goal | 7.30-7.45 |
Calculate Ideal Body Weight
Males: IBW (kg) = 50 + 2.3 × (height in inches - 60)
Females: IBW (kg) = 45.5 + 2.3 × (height in inches - 60)
Example: 5'10" male = 50 + 2.3 × (70-60) = 73 kg
Tidal volume = 73 × 6 = 438 mL (round to 440 mL)
PEEP/FiO2 Table (Lower PEEP/Higher FiO2)
| FiO2 | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 |
|---|---|---|---|---|---|---|---|---|
| PEEP | 5 | 5-8 | 8-10 | 10 | 10-14 | 14 | 14-18 | 18-24 |
Prone Positioning
Indications
- P/F ratio <150 despite optimized ventilation
- Within 36 hours of ARDS diagnosis
Protocol
Duration: ≥16 hours per day (ideally 16-20 hours)
Positioning: Carefully with team (prevent lines/tube issues)
Continue: Until P/F >150 on FiO2 ≤0.6 and PEEP ≤10
Benefits:
- Mortality reduction in severe ARDS (PROSEVA trial: NNT = 6)
- Improved V/Q matching
- Better lung recruitment
- Reduced VILI
Neuromuscular Blockade
Consider Early (First 48 Hours) If:
- Severe ARDS (P/F <150)
- Ventilator dyssynchrony
- Adjunct to prone positioning
Agent: Cisatracurium 15 mg bolus, then 37.5 mg/hr infusion
Evidence: ACURASYS trial showed mortality benefit; ROSE trial did not confirm. Use selectively.
Fluid Management
Conservative Fluid Strategy
- After initial resuscitation for shock
- Target CVP <4 or PAOP <8
- Diuretics to achieve net negative balance
- FACTT trial: Fewer ventilator days with conservative strategy
Recruit and Retain
Recruitment Maneuvers
- Transient increase in PEEP (30-40 cmH2O for 30-40 seconds)
- Evidence mixed; use with caution
- Monitor for barotrauma, hypotension
Corticosteroids
Current Evidence
- Dexamethasone 20mg × 5 days, then 10mg × 5 days (DEXA-ARDS trial)
- Started early in moderate-severe ARDS
- Reduces duration of mechanical ventilation and may reduce mortality
- Avoid in uncontrolled infection
ECMO (Extracorporeal Membrane Oxygenation)
Consider If:
- P/F <80 for >6 hours despite optimization
- P/F <50 for >3 hours
- pH <7.25 with PaCO2 >60 for >6 hours
- Murray score ≥3
Contraindications
- Mechanical ventilation >7 days
- Major contraindication to anticoagulation
- Poor baseline functional status
ICU Admission
- All patients with ARDS require ICU admission
- Invasive mechanical ventilation required in majority
- Continuous monitoring essential
- Prone positioning requires experienced team
Considerations for Transfer
Transfer to ARDS/ECMO Center If:
- Refractory hypoxemia despite optimal management
- ECMO may be indicated
- Lack of expertise in lung protective ventilation or proning
Prognosis Discussions
- Prepare family for prolonged ICU course
- Mortality 30-40% (higher in severe)
- Survivors may have long-term disability
- Goals of care discussions early
Understanding ARDS
- ARDS is severe lung inflammation causing very low oxygen levels
- It requires a breathing machine (ventilator) to support breathing
- Treatment focuses on allowing lungs to heal while preventing further damage
- Recovery takes weeks to months
What to Expect
- Patient will be sedated and on ventilator
- May need to lie on stomach (prone position) to help oxygen
- Multiple lines and monitors
- Daily updates from ICU team
- Prolonged ICU and hospital stay likely
Questions Families Should Ask
- What caused the ARDS?
- How severe is it (P/F ratio category)?
- What treatments are being used?
- Are there signs of improvement?
- What are the potential complications?
COVID-19 ARDS
Differences from Classic ARDS
- May have preserved lung compliance initially ("L-type")
- High thrombotic risk
- Prolonged course
- Dexamethasone proven beneficial (RECOVERY trial)
Management Modifications
- Awake proning if not intubated
- Anticoagulation (at least prophylactic, some use therapeutic)
- Tocilizumab/baricitinib in select patients
- Avoid delayed intubation
Immunocompromised Patients
- Higher mortality
- Consider atypical pathogens (PCP, CMV, Aspergillus)
- Bronchoscopy with BAL may be needed
- Empiric coverage may need to be broader
Pregnancy
- Prone positioning can be done with appropriate support
- ECMO used in severe refractory cases
- Delivery decisions based on gestational age and maternal status
- Multi-disciplinary approach essential
Trauma
- Pulmonary contusion may progress to ARDS
- Hemorrhage complicates fluid management
- Fat embolism syndrome in long bone fractures
- Aggressive pain control to prevent splinting
Performance Indicators
| Metric | Target |
|---|---|
| Lung protective ventilation (Vt ≤6 mL/kg IBW) | 100% |
| Plateau pressure ≤30 cmH2O | 100% |
| IBW calculated and documented | 100% |
| Prone positioning if P/F <150 | >0% |
| Daily spontaneous breathing trial when appropriate | 100% |
| DVT prophylaxis | 100% |
Documentation Requirements
- P/F ratio with calculation
- IBW calculation
- Ventilator settings with rationale
- Response to interventions
- Underlying cause identified or workup ongoing
- Family discussions documented
Diagnostic Pearls
- Always calculate P/F ratio - defines severity and guides treatment
- Bilateral infiltrates alone are not ARDS - need acute onset and hypoxemia
- Echo to exclude cardiogenic edema - especially if no clear ARDS trigger
- Find the underlying cause - ARDS is a syndrome, not a diagnosis
- P/F ratio requires PEEP ≥5 for Berlin criteria
Treatment Pearls
- 6 mL/kg IBW is non-negotiable - this saves lives
- Calculate IBW using height, NOT actual weight
- Prone early if P/F <150 - mortality benefit proven
- Accept permissive hypercapnia (pH >7.20) to maintain low Vt
- Conservative fluids after initial resuscitation
Disposition Pearls
- All ARDS goes to ICU - no exceptions
- Consider ECMO center transfer early - before patient is too sick to transport
- Prolonged course expected - prepare family
- Survivors need rehabilitation - functional impairment common
- Goals of care discussions should happen early
- ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
- Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes for acute lung injury and ARDS. N Engl J Med. 2000;342(18):1301-1308.
- Guérin C, et al. Prone positioning in severe acute respiratory distress syndrome (PROSEVA). N Engl J Med. 2013;368(23):2159-2168.
- Papazian L, et al. Neuromuscular blockers in early acute respiratory distress syndrome (ACURASYS). N Engl J Med. 2010;363(12):1107-1116.
- Villar J, et al. Dexamethasone treatment for the acute respiratory distress syndrome (DEXA-ARDS): a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276.
- Fan E, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;195(9):1253-1263.
| Version | Date | Changes |
|---|---|---|
| 1.0 | 2025-01-15 | Initial comprehensive version with 14-section template |